Tech Company Financing Transactions

Palvella Therapeutics Funding Round

Gore Range Capital, Petrichor Healthcare Capital Management and Agent Capital participated in a $37.7 million Series D capital raise for Palvella Therapeutics. The financing round was announced on 1/9/2023.

Transaction Overview

Company Name
Palvella Therapeutics
Announced On
1/9/2023
Transaction Type
Venture Equity
Amount
$37,700,000
Round
Series D
Investors

Gore Range Capital (Lead Investor)

Petrichor Healthcare Capital Management (Lead Investor) (Tadd Wessel)

Agent Capital

BioAdvance Ventures

BVF Partners

Nolan Capital

Samsara BioCapital (Cory Freedland)

Proceeds Purpose
Proceeds from the financing will be used to advance the development of Palvella's lead product candidate QTORIN� 3.9% rapamycin anhydrous gel (QTORIN� rapamycin) for the treatment of Pachyonychia Congenita (PC), treatment of Microcystic Lymphatic Malformations (Microcystic LM), and for the prevention of Basal Cell Carcinomas (BCCs) in Gorlin Syndrome (GS). QTORIN� rapamycin has received FDA Fast Track Designation for PC, Microcystic LM, and for the prevention of BCCs in GS.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
125 Strafford Ave. 360
Wayne, PA 19087
USA
Phone
(484) 253-1460
Website
www.palvellatx.com
Email Address
Not Recorded
Overview
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. We focus on developing therapies that specifically target the root cause of the disease.
Profile
Palvella Therapeutics LinkedIn Company Profile
Social Media
Palvella Therapeutics Company Twitter Account
Company News
Palvella Therapeutics News
Facebook
Palvella Therapeutics on Facebook
YouTube
Palvella Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Wes Kaupinen
  Wes Kaupinen LinkedIn Profile  Wes Kaupinen Twitter Account  Wes Kaupinen News  Wes Kaupinen on Facebook
Chief Financial Officer
Kathleen McGowan
  Kathleen McGowan LinkedIn Profile  Kathleen McGowan Twitter Account  Kathleen McGowan News  Kathleen McGowan on Facebook
Chief Scientific Officer
Braham Shroot
  Braham Shroot LinkedIn Profile  Braham Shroot Twitter Account  Braham Shroot News  Braham Shroot on Facebook
Vice President
Jason Connor
  Jason Connor LinkedIn Profile  Jason Connor Twitter Account  Jason Connor News  Jason Connor on Facebook
VP - Engineering
Gregory Coulter
  Gregory Coulter LinkedIn Profile  Gregory Coulter Twitter Account  Gregory Coulter News  Gregory Coulter on Facebook
VP - Operations
Emily Cook
  Emily Cook LinkedIn Profile  Emily Cook Twitter Account  Emily Cook News  Emily Cook on Facebook
VP - Operations
Kathy Goin
  Kathy Goin LinkedIn Profile  Kathy Goin Twitter Account  Kathy Goin News  Kathy Goin on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/9/2023: MediSked venture capital transaction
Next: 1/9/2023: C14 venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.